Targeting SIRT1 to inhibit the proliferation of multiple myeloma cells

BO LU*, DENGYANG ZHANG*, XIAOBO WANG, DONGJUN LIN, YUN CHEN and XIAOJUN XU

Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong 518107, P.R. China

Received August 1, 2020; Accepted December 23, 2020

DOI: 10.3892/ol.2021.12567

Abstract. Multiple myeloma (MM) is the second most common hematopoietic malignancy and remains an incurable disease. Thus, novel drugs and therapeutic methods are required for patients with MM. The present study aimed to investigate the effect of sirtuin 1 (SIRT1) inhibitor cambinol on the proliferation and apoptosis of myeloma cell lines, RPMI8226 and U266. Moreover, the present study evaluated the underlying molecular mechanisms of proliferation inhibition and apoptosis induced by cambinol. A Cell Counting Kit-8 assay was used to measure the viability of RPMI8226 and U266 cells treated with cambinol. Apoptosis and the cell cycle were analyzed via flow cytometry. The expression levels of caspase-3, poly(ADP-ribose) polymerase 1 (PARP), p53, acetylated p53 (Ac-p53), Bcl-2, cyclin D1 and p21 were detected in cells treated with cambinol using western blot analysis. The results demonstrated that cambinol inhibited the proliferation of RPMI8226 and U266 cells in a time- and dose-dependent manner. Increased apoptosis and G1 cell cycle arrest, together with enhanced procaspase-3 degradation and PARP cleavage were identified in cambinol-treated cells compared with controls. Western blotting results also revealed the upregulation of p53 acetylation and p21, as well as the downregulation of Bcl-2 and cyclin D1 in cells treated with cambinol. In conclusion, the present results suggest that cambinol inhibits the proliferation and induces apoptosis in RPMI8226 and U266 cells by regulating acetylation of p53 via the targeting of SIRT1.

Introduction

Multiple myeloma (MM) is a malignancy of plasma cells, and is the second most common type of hematopoietic malignancy, accounting for 10-15% of total hematopoietic cancer types (1). The prevalence of MM increases with age and the median age at diagnosis is 69 years old in the United States (1). Due to the development of novel drugs and therapeutic methods, the overall survival of patients with MM has significantly improved in recent decades (2). However, MM remains an incurable disease. One reason for this is the drug-resistance developed in patients during the treatment (3,4). Therefore, novel drugs and therapeutic methods are required to improve the treatment strategies for patients with MM.

In cancer, epigenetic regulation contributes to reversible modification of chromatin structure and gene transcription (5). Oncogenes are always upregulated or activated whereas tumor suppressor genes are always downregulated or silenced in this process (5). Acetylation/deacetylation is one of the mechanisms that is involved in this regulatory process. Lysine residues of histone or non-histone can be acetylated by histone/protein acetyltransferases, which is contrary to the activity of histone deacetylases (HDAC) (6). Deacetylation of histone or non-histone can lead to transcription silence of genes and deactivation of protein (6,7). In cancer cells, inhibition of HDAC leads to cell cycle arrest and induction of apoptosis. Targeted inhibition of HDAC may therefore be considered as a potential therapeutic method in MM treatment (8).

The silent mating type information regulation 2 homolog (SIRTUIN) family belongs to Class III HDACs and is a group of proteins with nicotinamide adenine dinucleotide (NAD)-dependent deacetylase activity (9). Their substrates include histone and non-histone proteins (9). It has important roles in cancer cell survival and apoptosis by deacetylating key cell signaling molecules and apoptotic related proteins, including TATA binding protein-associated factor 168, p53 and forkhead box O1 (FOXO1) (10). Among the SIRTUIN family, silent mating type information regulation 2 homolog 1 (SIRT1) is the most-studied member in basic and translational oncology research (11,12). Previous studies have reported that SIRT1 contributes to the development of several solid tumors and hematopoietic malignancies (13,14). In addition, small compounds targeting SIRT1 could effectively inhibit the proliferation of tumor cells. Therefore, the present
study aimed to investigate the antitumor effect of the SIRT1 inhibitor cambinol on MM cells.

Materials and methods

Reagents and cell lines. MM cell lines RPMI8226 and U266 were ordered from the American Type Culture Collection. A Cell Counting Kit (CCK)-8 assay was purchased from Beyotime Institute of Biotechnology. Cambinol, Annexin V and PI were purchased from Sigma-Aldrich (Merck KGaA). Anti-pro-caspase-3 (cat. no. 610322; 1:1,000), and poly(ADP-ribose) polymerase 1 (PARP) (cat. no. 556362; 1:2,000) antibodies were purchased from BD Biosciences. The anti-β-actin antibody (cat. no. ZRB1312; 1:1,000) was purchased from Sigma-Aldrich (Merck KGaA). Anti-p53 (cat. no. 48818; 1:1,000), cleaved caspase 3 (cat. no. 9664; 1:1,000), acetylated p53 (Lys382; Ac-p53) (cat. no. 2525; 1:1,000), Bcl-2 (cat. no. 15071; 1:1,000), cyclin D1 (cat. no.2922; 1:1,000) and p21 (cat. no. 2947; 1:1,000) antibodies were purchased from Cell Signaling Technology, Inc. The anti-mouse and rabbit horseradish peroxidase-conjugated secondary antibodies (cat. no. 7076, 7074; 1:5,000) were purchased from Cell Signaling Technology, Inc. Culture RPMI-1640 medium and FBS were purchased from Cytiva. Fluorescence Activated Cell Sorter (FACS) was obtained from BD Biosciences.

Cell viability assay. MM cells were routinely cultured in RPMI-1640 medium supplemented with 10% FBS at 37°C in a humidified incubator with 5% CO2. For the proliferation assay, cells were seeded in 96-well plate at a density of 2x10^4 cell/well. The cells were incubated with various concentrations of cambinol (20, 40, 80, 160 and 320 µM) dissolved in DMSO for 24 and 48 h (at 37°C in 5% CO2). Then, 20 µl CCK-8 solution was added to each well and the cells were incubated at 37°C in 5% CO2 for 4 h according to the manufacturer’s protocol. The absorbance was measured at 450 nm and values are presented as mean ± SD.

Cell apoptosis assay. Apoptosis measurement was performed according to the protocol of Annexin V-FITC Apoptosis Detection Kit (Beyotime Institute of Biotechnology). Cells were treated with 80 µM cambinol for 48 h at 37°C in 5% CO2 and were collected via centrifugation (1,000 x g for 5 min at 4°C). Then, cells were washed once with 1X washing buffer. Cells were resuspended in 500 µl working staining solution and incubated in ice for 5 min, subsequently 5 µl Annexin V was added. Then, 5 µl PI solution was added to each tube and cells were incubated in ice for 15 min, the cells were detected using FACS. Results are representative of three independent experiments.

Cell cycle analysis. Cells were treated with 80 µM cambinol at 37°C for 48 h and were collected via centrifugation (1,000 x g for 5 min at room temperature). The collected cells were resuspended in 70% ethanol and incubated at -20°C overnight. On the following day, cells were washed twice with PBS and resuspended in 0.5 ml PBS containing 0.1% Triton X-100, 0.2 mg/ml DNase-free RNase and 2 µg/ml PI. Cells were incubated on ice in the dark and cell cycle was assessed via FACS within 2 h.

SIRT1 activity assay. SIRT1 activity was analyzed using a fluorogenic SIRT1 assay kit (cat. no. CS1040; Sigma-Aldrich; Merck KGaA). According to the manufacturer’s instructions, whole cell lysate proteins were extracted with RIPA buffer (Beyotime Institute of Biotechnology) and the fluorogenic SIRT1 assay kit was used to perform the assay.

Western blotting. After drug treatment for 48 h, cells in a 60-mm culture dish were washed twice with PBS, lysed in 150 µl ice-cold high-efficiency RIPA buffer with the protease inhibitor PMSF (1 mM) for 30 min, then collected to a 1.5 ml tube and centrifuged at 4°C 12,000 x g for 10 min. The protein concentration was quantified in supernatant using a BCA assay kit. The supernatant was mixed with 5X loading buffer and heated at 100°C for 5 min and samples (40 µg per lane) were loaded and separated via SDS-PAGE (10% separating gel). The 0.2-µm PVDF membrane was used for protein transfer. Membranes were blocked with 5% non-fat dry-milk in TBS-Tween-20 (TBST; 0.1% v/v Tween-20) for 1 h at room temperature, and then incubated with the primary antibodies overnight at 4°C. After washing three times with TBST, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. The membranes were washed three times with TBST, and incubated with chemiluminescent substrates (Santa Cruz Biotechnology, Inc.). Protein semi-quantification was conducted with ImageJ software (National Institutes of Health). Results are representative of three independent experiments.

Statistical analysis. Data are presented as the mean ± SD. Differences between two groups were determined using unpaired two-sample Student’s t-test. Comparisons between multiple groups were determined using a one-way ANOVA with Bonferroni post hoc analysis. Significance was analyzed using GraphPad Prism 6.0 (GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

Cambinol inhibits the proliferation of RPMI8226 and U266 cells. The inhibitive effect of cambinol on MM cell proliferation was measured using a CCK-8 assay. RPMI8226 and U266 cell lines were treated with different concentrations (20, 40, 80, 160 and 320 µM) of cambinol for 24 and 48 h. It was demonstrated that cambinol inhibited the proliferation of RPMI8226 and U266 cells in a dose- and time-dependent manner. IC50 values of cambinol on RPMI8226 and U266 were ~77.24 and 79.23 µM, respectively, following the 48 h treatment (Fig. 1A and B).

Cambinol induces apoptosis in RPMI8226 and U266 cells. The apoptosis-inducing effect of cambinol on RPMI8226 and U266 cell lines was measured via FACS. MM cells were cultured with 80 µM cambinol for 48 h. FACS data demonstrated that the apoptotic rate of RPMI8226 cells increased from 11.43% in the control group to 55.72% in the drug-treated group (Fig. 2A), and the rate of apoptosis of U266 cells increased from 6.3% in control group to 36.71% in the drug-treated group (Fig. 2B). These data indicate that cambinol significantly induced apoptosis in RPMI8226 and U266 cells.

Cambinol induces cell cycle arrest in RPMI8226 and U266 cells. To examine the effect of cambinol on the cell cycle
of RPMI8226 and U266 MM cells, cells were treated with cambinol for 48 h, and then analyzed via FACS after staining with PI. For RPMI8226 cells, the percentage of cells in the G1 phase was 24.23% in the control group, which increased to 39.73% in the drug-treated group. For U266 cells, 43.03% of cells were in the G1 phase in the control group, which increased to 66.33% in the drug-treated group (Fig. 3).

Inhibition of cambinol on SIRT1 activity and the effect on protein expression levels in RPMI8226 cells. RPMI8226 cells were treated with different concentrations (0, 40, 80 and 160 µM) of cambinol for 48 h and then lysed with RIPA buffer. SIRT1 activity was analyzed using an SIRT1 assay kit. It was demonstrated that cambinol decreased SIRT1 activity in a dose-dependent manner (P<0.001; Fig. 4A). Western blotting
Figure 3. Effect of cambinol on the induction of cell cycle arrest in RPMI8226 and U266 cells. RPMI8226 and U266 cells were treated with 80 µM cambinol for 48 h, and cells were analyzed via FACS after PI staining. Accumulation in the G1 phase was observed in RPMI8226 and U266 cells treated with cambinol. **P<0.01 and ***P<0.001.

Figure 4. Effect of cambinol on protein expression levels in RPMI8226 cells. Western blotting was performed to assess the protein expression levels in RPMI8226 cells following 48 h treatment with 0, 40, 80 and 160 µM cambinol. (A) SIRT1 activity was detected using a SIRT1 Assay kit. (B) Expression levels of PARP and pro-caspase-3. (C) Expression levels of the Ac-p53, p53, Bcl-2, CyclinD1 and p21. β-actin expression was used as a loading control for each panel. *P<0.05, **P<0.01 and ***P<0.001. Ac-p53, Acetylated p53; SIRT1, silent mating type information regulation 2 homolog 1; PARP, poly(ADP-ribose) polymerase 1.
was used to measure expression levels of PARP, caspase3, p53, Ac-p53, Bcl-2, cyclin D1 and p21. It was identified that the expression levels of cleaved PARP, cleaved caspase3, Ac-p53 and p21 were upregulated in a dose-dependent manner, while the expression levels of procaspase3, Bcl-2 and cyclin D1 were downregulated (Fig. 4B and C).

Discussion

SIRT1 belongs to class III histone deacetylases (HDAC) and it is a homologue protein of yeast silent information regulator 2 (Sir2). The de-acetylation activity of type III HDACs depends on the cofactor NAD, which is dispensable for type I and type II HDACs. The human SIRTuin family is homologue to Sir2, and these are highly conservative from bacteria to humans. SIRT1 and SIRT2 of the SIRTuin family have highly similar sequences, and are associated with cell apoptosis, the cell cycle, DNA repair, DNA recombination and gene silencing (15,16).

SIRT1 deacetylates histone H3 and histone H4. It also interacts with transcription factors or co-factors, including p53, FOXO family member, NF-κB, myoblast determination protein 1, nuclear receptor corepressor, p300 and peroxisome proliferator-activated receptor γ coactivator 1-α, and regulates their transcriptional activity. SIRT1 inhibitors exhibit antitumor activity, which has been observed in cells from breast, thyroid, lung, pancreatic, prostate, hepatitis and colon cancer (17-21). Moreover, SIRT1 has effective antitumor activity against hematological malignancies, such as T/B-cell lymphoma, chronic myeloid leukemia (CML), leukemia and other hematological malignancies (11,22-26). Cambinol is an inhibitor of SIRT1/2 that has been identified to exert antitumor activity and low toxicity in murine models (27,28). The present results demonstrated that cambinol exhibited anti-proliferative effects on RPMI8226 and U266 cell lines that were dose- and time-dependent. Previous studies have reported that the antitumor activity of SIRT1 inhibitors was the result of cell apoptosis and cell cycle arrest (27). In primary exudative lymphoma, SIRT1 inhibitors were found to induce cell apoptosis and cell cycle arrest at the G1 phase (24). When treated with cambinol, the proliferation of hepatic cancer cells is inhibited and the tumor burden in mice is also significantly reduced (27). The present results demonstrated that cambinol suppressed the activity of SIRT1, promoted cell apoptosis and arrested the cell cycle at the G1 phase in MM cells.

p53 is a tumor suppressor, which is actively involved in tumor occurrence and development. The antitumor function of p53 is mediated via two pathways: Transcription-dependent or -independent signaling pathways. As a transcription factor, p53 can activate the transcription and expression of multiple target genes to regulate cell apoptosis, including growth arrest and DNA damage inducible α, murine double minute-2, p21, Bax, fas, insulin-like growth factor-binding protein 3 and TNF receptor superfamily member 10b. p53 can also activate apoptosis by interacting with target proteins directly, which is another effective cell-regulating mechanism (29). p53 can be activated by acetylation (30). Using a SIRT1 inhibitor or gene silencing methods, the protein level of acetylated p53 can be increased in CML cells, and the elimination of CML stem cells can be further potentiated when combined with imatinib (a tyrosine kinase inhibitor) (31). The SIRT1 inhibitor regulates downstream-associated proteins and cyclins through increasing the active form of p53 and decreasing Bcl-2 protein and cyclin D1. Also, the SIRT1 inhibitor reduces the cell proliferation rate and induces apoptosis in breast cancer cell (32).

MM is currently recognized as an incurable tumor type, due to drug resistance. The application of novel drugs is an effective method to improve the survival of patients with MM. Cambinol was investigated to inhibit cell viability in hepatocellular carcinoma, breast cancer, prostate cancer and human glioma cell lines (33-36), and also exhibits antitumor activity. According to the literature, to the best of our knowledge, no studies have examined the effect and mechanism of cambinol in MM cells. The present study demonstrated the antitumor activity of cambinol on MM cells and described the potential mechanism. Moreover, further studies to increase the potency and selectivity towards SIRT1 or SIRT2 for enhanced their antitumor efficacy are underway. Cambinol analogs may be beneficial for sensitizing tumor cells to other chemotherapeutic agents (37,38). Thus, cambinol and its analogs are promising antitumor agents for MM.

In conclusion, the present study investigated the effect of cambinol on MM cell lines-RPMI8226 and U266, and found that cambinol can inhibit proliferation, and induce apoptosis of MM cells. The possible underlying mechanism of cambinol on MM cells involves the upregulation of acetylation p53 protein through inhibition of SIRT1. The results of this study provide evidence for the further clinical use of cambinol or its analogs in treating patients with MM.

Acknowledgements

Not applicable.

Funding

This study was supported by the Sanming Project of Medicine in Shenzhen (grant no. SZSM201911004) and the hospital research fund of The Seventh Affiliated Hospital Sun Yat-sen University (grant no. ZSQYLCKYJ202027).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

XX and BL conceived and designed all the experiments. BL and DZ performed the experiments. XW, YC and DL analyzed the experimental data. BL and DZ contributed to manuscript preparation, writing, editing and revision. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.
Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Lynch HT, Watson P, Tarantolo S, Wiernick PH, Quinn-Laquer B, Isgur Bergsagel K, Huiart L, Olopade OL, Sobol H, Sanger W, et al.: Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 23: 685-693, 2005.

2. Terpos E and International Myeloma Society: Multiple myeloma: Clinical updates from the American Society of hematology annual meeting. 2017. Clin Lymphoma Myeloma Leuk 18: 321-334, 2018.

3. Robak P, Drozdz I, Szemraj J and Robak T: Drug resistance in multiple myeloma. Cancer Treat Rev 70: 199-208, 2018.

4. Xu XH, Liu J, Shen CY, Ding LL, Zhong F, Ouyang Y, Wang YC and He S: The role of ubiquitin-specific protease 14 (USP14) in cell adhesion-mediated drug resistance (CAM-DR) of multiple myeloma cells. Eur J Haematol 98: 4-12, 2017.

5. Liu M, Jiang L and Guan XY: The genetic and epigenetic alterations in human hepatocellular carcinoma: A recent update. Protein Cell 5: 673-691, 2014.

6. Khochbin S, Verdel A, Lemerrier C and Seigneurin-Berry D: Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 16: 116-166, 2006.

7. Tang Y, Zhao W, Chen Y, Zhao Y and Gu W: Acetylation is indispensable for p53 activation. Cell 133: 612-626, 2008.

8. Conte M, De Palma R and Altucci L: HDAC inhibitors as epigenetic regulators for cancer immunotherapy. Int J Biochem Cell Biol 98: 65-74, 2018.

9. Jin X, Wei Y, Xu F, Zhao M, Dai K, Shen R, Yang S and Zhang N: SIRT1 promotes formation of breast cancer through modulating Akt activity. J Cancer 9: 2012-2023, 2018.

10. Kumar A and Chauhan S: How much successful are the medicinal chemists in modulation of SIRT1: A critical review. Eur J Med Chem 119: 45-69, 2016.

11. Roth M, Wang Z and Chen WY: Sirtuins in hematological aging and malignancy. Crit Rev Oncog 18: 531-547, 2013.

12. Hwang ES and Song SB: Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells. Cell Mol Life Sci 74: 3347-3362, 2017.

13. Li L and Bhattacharjee A: Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells. Curr Opin Hematol 22: 324-329, 2015.

14. Tae IH, Park EY, Dey P, Son JY, Lee SY, Jung JH, Saloni S, Hwang ES and Song SB: Nicotinamide is an inhibitor of SIRT1 of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21: 266-281, 2012.

15. Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD and Lam EW: SIRT1 inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 9: 844-855, 2010.

16. Ceballos MP, Decandio G, Quirao AD, Comanzo CG, Livore VI, Lorenzetti F, Lambertucci F, Chazarreta-Cifre L, Banchio C, Alvarez ML, et al.: Inhibition of siurnin 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRPs in heptatoocellular carcinoma cell lines. Toxicol Lett 289: 63-74, 2018.

17. Dykes SS, Friday E, Pruit K and Cardellia JA: The histone deacetylase inhibitor carbinol prevents acidic pH-induced anterograde lysosome traficking independently of siurnin activity. Biochem Biophys Res 3: 83-91, 2013.

18. Simmons GE Jr, Pandey S, Nedeljkovic-Kurepa A, Saxena M, Wang A and Pruit K: Frizzled 7 expression is positively regulated by SIRT1 and β-catenin in breast cancer cells. PLoS One 9: e98861, 2014.

19. Holloway KR, Barbieri A, Malyarchuk S, Saxena M, Nedeljkovic-Kurepa A, Cameron Mehl M, Wang A, Gu X and Pruit K: SIRT1 positively regulates breast cancer-associated human aromatase (CYP19A1) expression. Mol Endocrinol 27: 63-74, 2018.

20. Botta L, Filippi S, Bizzarri BM, Meschini R, Caputo M, Proietti-De-Santis L, Iside C, Nebbiob G, Guandia L and Saladinoca R: Oxidative nuclearileich substitution selectively produces carbinol derivatives with antiproliferative activity on bladder cancer cell lines. Bioorg Med Chem Lett 29: 78-82, 2019.

21. Mahajan SS, Scian M, Srapth S, Posakony J, Li H, Goeche S, Kollipara R, Depinho RA, Gu Y, Simon JA and Bedalov A: Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66: 4368-4377, 2006.

22. Zhou L, Wang Q, Chen X, Fu L, Zhang X, Wang L, Deng A, Li D, Liu J, Lv N, et al.: AML1-ETO promotes SIRT1 expression to enhance leukemogenesis of t(8;21) acute myeloid leukemia. J Hematol Oncol 46: 62-69, 2017.

23. Sharma VK, Raimondi V, Ruggiero K, Pise-Masison CA, Cavallari I, Silic-Benussi M, Cinimale V and D’Agostino DM: Expression of miR-34a in T-cells infected by human T-Lymphotropic Virus 1. Front Microbiol 9: 832, 2018.

24. He M, Tan B, Vasan K, Yuan H, Cheng F, Ramos da Silva S, Lu C and Gao SF: SIRT1 and AMPK pathways are essential for the proliferation and survival of primary effusion lymphoma cells. J Pathol 242: 309-321, 2017.

25. Bhalia S and Gordon LI: Functional characterization of NAD dependent de-acetylases SIRT1 and SIRT2 in B-cell chronic lymphocytic leukemia (CLL). Cancer Biol Ther 17: 300-309, 2016.

26. Kim HB, Lee SH, Um JH, Oh WK, Kim DW, Kang CD and Kim SH: Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1. Oncotarget 6: 36202-36218, 2015.

27. Portmann S, Fahrner R, Lechleiter A, Keogh A, Overney S, Laemmle A, Mikami K, Montani M, Tschan MP, Candinas D and Stroka D: Antitumor effect of SIRT1 inhibition in human HCC tumor models in vitro and in vivo. Mol Cancer Ther 12: 399-508, 2013.

28. Liu L, Bhatia R, Gauthon T, Schuler AD, Posakony J, Li H, Goche S, Kollipara R, Depinho RA, Gu Y, Simon JA and Bedalov A: Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66: 4368-4377, 2006.

29. Hwang J: Current developments of targeting the p53 signaling pathway for cancer treatment. Pharmacol Ther Oct 29, 2020 (Epub ahead of print). doi: 10.1016/j.pharmthera.2020.107720.

30. Brooks CL and Gu W: New insights into p53 activation. Cell Res 20: 614-621, 2010.

31. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, Holyoke TL, Chen W and Bhattacharjee A: Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21: 266-281, 2012.

32. Prue K, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD and Lam EW: SIRT1 inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 9: 844-855, 2010.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.